Effect of chronic angiotensin converting enzyme inhibitor therapy on myocardial injury in XXXX undergoing percutaneous coronary interventions.

@entity1 @entity712 @entity6 @entity63 @entity75 @entity299 @entity1011 @entity583 @entity204
BACKGROUND: Procedural @entity583 is a frequent complication of percutaneous coronary intervention (PCI). Angiotensin converting enzyme inhibitors (ACE-I) have been shown to reduce @entity63 events in the setting of acute @entity583 ( @entity583 ) and @entity712 . OBJECTIVE: We sought to evaluate whether chronic ACE-I treatment prior to PCI reduces the incidence of procedural @entity583 . METHODS: The study cohort included consecutive @entity1 from January 2003 to August 2004 undergoing PCI with normal baseline serum @entity1011 kinase (CK) and cardiac CK isoform (CK-MB) (n = 265). Procedural @entity583 was defined as CK-MB elevation >=  3 times the upper limit of normal. RESULTS: @entity1 on chronic ACE-I had a higher baseline prevalence of adverse prognostic features including @entity6 (p = 0.02) and a trend towards a lower incidence of drug-eluting stent use (p = 0.07). Using multiple logistic regression, @entity1 on chronic ACE-I therapy (n = 138) had a 64% reduction in procedural @entity583 compared with those not on ACE-I (n = 127; odds ratio = 0.36; 95% confidence intervals 0.13-0.99; p = 0.05). Long-term outcomes, including @entity204 and major adverse @entity299 (MACE) (combined total of @entity204 , @entity583 and @entity75 revascularization were similar in the two groups. Procedural @entity583 was, however, associated with increased MACE during follow up (60% vs. 35.4%; p = 0.035). CONCLUSION: Chronic ACE-I therapy before PCI may reduce the incidence of procedural @entity583 .
